Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens

Darrigrand, Pierson et al. study the effect of mRNA splicing inhibitors on the generation of the MHC class I ligands. They developed a derivative of the spliceosome inhibitor isoginkgetin which is less toxic and more effective at enhancing antigen presentation and CD8+ T cell activation and showed g...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Romain Darrigrand, Alison Pierson, Marine Rouillon, Dolor Renko, Mathilde Boulpicante, David Bouyssié, Emmanuelle Mouton-Barbosa, Julien Marcoux, Camille Garcia, Michael Ghosh, Mouad Alami, Sébastien Apcher
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/1c8392da73b6409daf3965425089b16d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1c8392da73b6409daf3965425089b16d
record_format	dspace
spelling	oai:doaj.org-article:1c8392da73b6409daf3965425089b16d2021-12-02T13:19:27ZIsoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens10.1038/s42003-021-01801-22399-3642https://doaj.org/article/1c8392da73b6409daf3965425089b16d2021-03-01T00:00:00Zhttps://doi.org/10.1038/s42003-021-01801-2https://doaj.org/toc/2399-3642Darrigrand, Pierson et al. study the effect of mRNA splicing inhibitors on the generation of the MHC class I ligands. They developed a derivative of the spliceosome inhibitor isoginkgetin which is less toxic and more effective at enhancing antigen presentation and CD8+ T cell activation and showed greater antitumour activity in vivo. These findings identify the spliceosome as a druggable target for the development of epitope-based immunotherapies.Romain DarrigrandAlison PiersonMarine RouillonDolor RenkoMathilde BoulpicanteDavid BouyssiéEmmanuelle Mouton-BarbosaJulien MarcouxCamille GarciaMichael GhoshMouad AlamiSébastien ApcherNature PortfolioarticleBiology (General)QH301-705.5ENCommunications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Biology (General) QH301-705.5
spellingShingle	Biology (General) QH301-705.5 Romain Darrigrand Alison Pierson Marine Rouillon Dolor Renko Mathilde Boulpicante David Bouyssié Emmanuelle Mouton-Barbosa Julien Marcoux Camille Garcia Michael Ghosh Mouad Alami Sébastien Apcher Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens
description	Darrigrand, Pierson et al. study the effect of mRNA splicing inhibitors on the generation of the MHC class I ligands. They developed a derivative of the spliceosome inhibitor isoginkgetin which is less toxic and more effective at enhancing antigen presentation and CD8+ T cell activation and showed greater antitumour activity in vivo. These findings identify the spliceosome as a druggable target for the development of epitope-based immunotherapies.
format	article
author	Romain Darrigrand Alison Pierson Marine Rouillon Dolor Renko Mathilde Boulpicante David Bouyssié Emmanuelle Mouton-Barbosa Julien Marcoux Camille Garcia Michael Ghosh Mouad Alami Sébastien Apcher
author_facet	Romain Darrigrand Alison Pierson Marine Rouillon Dolor Renko Mathilde Boulpicante David Bouyssié Emmanuelle Mouton-Barbosa Julien Marcoux Camille Garcia Michael Ghosh Mouad Alami Sébastien Apcher
author_sort	Romain Darrigrand
title	Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens
title_short	Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens
title_full	Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens
title_fullStr	Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens
title_full_unstemmed	Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens
title_sort	isoginkgetin derivative ip2 enhances the adaptive immune response against tumor antigens
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1c8392da73b6409daf3965425089b16d
work_keys_str_mv	AT romaindarrigrand isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens AT alisonpierson isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens AT marinerouillon isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens AT dolorrenko isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens AT mathildeboulpicante isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens AT davidbouyssie isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens AT emmanuellemoutonbarbosa isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens AT julienmarcoux isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens AT camillegarcia isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens AT michaelghosh isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens AT mouadalami isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens AT sebastienapcher isoginkgetinderivativeip2enhancestheadaptiveimmuneresponseagainsttumorantigens
_version_	1718393257230073856

Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens

Ejemplares similares